Welcome, Guest. Please login or register.
May 29, 2024, 05:47:54 pm

Login with username, password and session length


Members
  • Total Members: 6309
  • Latest: Vicki
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 137
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 113
Total: 113

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Sovaldi’s Arrival Tied to Better Outcomes in Those on Liver Transplant Waiting..  (Read 5289 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The introduction of Gilead Sciences’ hepatitis C virus (HCV) Sovaldi (sofosbuvir) to the market in December 2013 was associated with improvements in the health outcomes of those living with the virus who were on the liver transplant waiting list.

Sovaldi ushered in the current era of highly effective direct-acting antiviral (DAA) treatment. The drug was incorporated into Gilead’s Harvoni (ledipasvir/sofosbuvir), which was approved in October 2014 and became a blockbuster drug. Various other DAAs from other pharmaceutical companies emerged from the pipeline during this time, leading to today’s healthy crop of numerous, highly effective hep C regimens.

For more...
https://www.hepmag.com/article/sovaldis-arrival-tied-better-outcomes-liver-transplant-waiting-list

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.